The NHS is doing its bit to make England a more attractive place to develop drugs, with a new plan to cut costs and improve data and technology support for clinical trials.
Simon Stevens hails success in negotiating with pharma companies on price and data, and has defended NHS England’s record in promoting innovative medicines.
The UK pharma industry association yesterday declared war on the latest NHS price control system – but the UK biotech industry counterpart seems far from convinced the move is helpful.
The UK pharma industry association has launched legal action against a newly-introduced measure which it says will unfairly delay or deny access to new medicines.